Lung (includes NSCLC, SCLC, Mesothelioma)

FDA Approves Roche’s Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Adults With Extensive-stage Small Cell Lung Cancer

(Roche) Mar 19, 2019 - Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC). First new initial treatment option approved by FDA for people with ES-SCLC in more than 20 years.

read corporate press release

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer

(NRG Oncology) Mar 18, 2019 - Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. Cumulative brain metastases (BM) rates are high for patients with LA-NSCLC. NRG Oncology conducted the NRG-RTOG 0214 trial to address this high incidence of brain metastases and determine if the addition of PCI following primary treatment improved overall survival (OS) in patients with LA-NSCLC.

read press release

Roche Gets FDA Nod For Tecentriq In Small Cell Lung Cancer

(PMLiVE [UK]) Mar 19, 2019 - Roche continues to nibble away at the big lung cancer market with its cancer immunotherapy Tecentriq, picking up an FDA approval for first-line extensive-stage small cell lung cancer (ES-SCLC). The US regulator has cleared Tecentriq (atezolizumab) in combination with chemotherapy for ES-SCLC, making the PD-L1 inhibitor the first cancer immunotherapy to be approved as initial therapy in this cancer and ending a 20-year drought in new therapies for patients. SCLC is less common than non-small cell lung cancer (NSCLC) but tends to be more aggressive, growing more quickly and spreading to other parts of the body earlier.

read article

Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations

(Rain Therapeutics) Mar 19, 2019 - Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced that it has dosed the first patient in its Phase 2 clinical trial of tarloxotinib (Tarlox).

read corporate press release

New Partnership Between LUNGevity Foundation, Pattern.org, and the Broad Institute Empowers Patients to Be Partners in Research

(LUNGevity Foundation) Mar 18, 2019 - Tissue collection will increase the number of high-quality lung cancer samples to develop cancer models.

read press release

New Report Finds States Must Do More To Ensure People At High Risk Can Be Screened For Lung Cancer

(MD Anderson) Mar 19, 2019 - American Lung Association, MD Anderson partnership seeks to ensure access to screening for those at high risk for lung cancer through state Medicaid programs.

read press release

Biodesix VeriStrat Data Demonstrate Independent Prediction of Immunotherapy Outcomes for NSCLC Patients

(MarketWatch) Mar 14, 2019 - Biodesix® today presented new data demonstrating that the VeriStrat® test is predictive of outcomes for patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting, even when adjusted for PD-L1 status.

read article

AstraZeneca Showcases Next-generation Oncology Pipeline Addressing Unmet Patient Needs At AACR Annual Meeting

(AstraZeneca) Mar 14, 2019 - AstraZeneca will share pioneering research and development across its successful Oncology portfolio and extensive next-generation pipeline at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, USA, 29 March to 3 April 2019. The new research will showcase AstraZeneca’s potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor, taking the DNA Damage Response (DDR) pipeline beyond PARP inhibition. Additional highlights include new insights from the MYSTIC and TATTON trials for Imfinzi (durvalumab) and Tagrisso (osimertinib) in predicting response and addressing treatment resistance in lung cancer. In total, data from 84 presentations will illustrate the progress of AstraZeneca’s Oncology pipeline, with 28 abstracts reporting new Immuno-Oncology (IO) data, 33 focused on complementary biological pathways exploring the DDR mechanism, and 20 on tumour drivers and resistance mechanisms.

read corporate press release

ZEB1 Throttles Therapeutic Target, Protecting KRAS-mutant Lung Cancer

(MD Anderson) Mar 13, 2019 - Protein forces a shift in cell type, a plasticity that promotes resistance to targeted therapy.

read press release

New Lung Cancer Indication For Keytruda Combo Ok’d In EU

(PharmaTimes [UK]) Mar 14, 2019 - MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).

read article

New Lung Cancer Studies Feature Latest Treatment Advances

(ASTRO) Mar 12, 2019 - New research released today provides guidance for physicians who treat patients with lung cancer. Three authors will present their findings in an online presscast today and during the plenary session Thursday, March 14, at the 2019 Multidisciplinary Thoracic Cancers Symposium, held March 14-16.

read press release

Blood Tumor Mutational Burden Could Identify Benefit from Checkpoint Inhibitors in NSCLC

(Curetoday.com) Mar 13, 2019 - A cancer gene panel using blood may be a cost-effective way of testing the quantity of mutations found in tumors of patients with non-small cell lung cancer.

read article

Artificial Intelligence Cuts Lung Cancer False Positives

(UPMC) Mar 12, 2019 - This is the first time artificial intelligence has been applied to the question of sorting out benign from cancerous nodules in lung cancer screening.

read press release

Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

(Lilly) Mar 12, 2019 - Eli Lilly and Company today announced that its Phase 3 RELAY study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment. The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have activating EGFR mutations.

read corporate press release

Lilly’s Cyramza Hits Mark In First-Line Lung Cancer Trial

(Pharmaphorum.com [UK]) Mar 12, 2019 - Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche’s Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings with regulators later this year. Already approved in second-line lung cancer and gastric and stomach cancers, Lilly is looking for further uses for the drug that blocks blood supply to tumours. Lilly said results from the phase 3 study showed Cyramza in combination with Tarceva (erlotinib) met its primary endpoint of progression-free survival, demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment.

read article

European Commission Approves Roche’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

(Roche) Mar 8, 2019 - Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) compared with Avastin plus chemotherapy. New treatment option for EGFR mutant or ALK-positive non-small cell lung cancer patients after appropriate targeted therapy.

read corporate press release

Helsinn Initiates Two New Global Phase III Studies With Anamorelin

(Helsinn) Mar 7, 2019 - Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and cachexia.

read corporate press release

Roche Gets European Approval For Tecentriq Combo Vs. Lung Cancer

(Reuters) Mar 8, 2019 - Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday. The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases, Roche said.

read article

Two for the Price of One: Mechanistic Insights Lead to Drug Repositioning

(University of Tsukuba [Japan]) Mar 7, 2019 - A new study reported in the journal Clinical Cancer Research has raised hopes in this field by revealing how a cancer-promoting protein called stratifin causes lung adenocarcinoma to emerge.

read article

AI Trained To Identify Lung Cancer Is Now As Smart As A Pathologist

(NY Post/BGR) Mar 5, 2019 - Researchers from Dartmouth’s Norris Cotton Cancer Center have announced their development of a deep neural network that can identify lung cancer on tissue slides with accuracy that matches a human pathologist.

read article
Next Page